Survival Analysis Of Postoperative Breast Cancer Patients With Different Molecular Subtypes

Objectives To find out the distribution of clinicopathological features and survival status of breast cancer patients with different molecular subtypes, by clinical follow-up study in Hebei United University affiliated hospital from Jan 2004 to Dec 2009 so as to enrich Chinese female breast cancer molecular classification related data, and to provide the theoretical and basis for the individual therapy.Methods Breast cancer patients were selected as subjects in Hebei United University affiliated hospital from Jan 2004 to Dec 2009. And baseline data including clinical data and molecular subtype's data were collected and the 5-year survival status was followedup by 2 graduates through phone and case record. Luminal A, Luminal B, Her-2 positive subtype and triple negative subtype were classified according to immunohistochemistry results of ER, PR and Her-2. Observe the patients' prognosis of different molecular subtypes.The database was built by excel 2003 and was analyzed by SPSS sorftware.Results 1 In all 283 cases of breast cancer, Luminal A subtype accounted for 175 cases(61.8%), Luminal B subtype 35 cases(12.4%), Her-2 positive subtype 26 cases(9.2%)and triple negative subtype 47 cases(16.6%). 2 The average age of the patients' was(49.8±9.3), there was no difference in the different subtypes. However the average age of Her-2 positive subtype patients were the youngest(47.9±10.6) in four subtype's patients. 3The patients of different molecular subtypes were different from tumor size, clinical stage and radiation therapy. The proportion of T2 and T3 tumor phase patients in Her-2 positive subtype cases Triple negative subtype and triple negative subtype have the highest proportion of(73.1% and 61.7%). Luminal A subtype cases have the highest proportion of clinical stage I(29.1%). Triple negative subtype cases have the highest proportion of clinical stage II and III(80.9%), the second is Her-2 positive subtype(80.8%), the third is Luminal B subtype(74.3%). 4 Different molecular subtypes have different 3-year and 5-year overall survival and disease free survival by Kaplan-Meier analysis(P < 0.05).Compared with Luminal A, Luminal B had no difference in 3-year and 5-year OS and DFS(P > 0.05), Her-2 positive subtype and triple negative subtype had difference respectivelty in 3-year and 5-year OS and DFS(P<0.05) by parewise comparison. 5 After adjusting age, clinical data by COX analysis molecular subtype was not an independent risk factor for breast cancer patients' prognosis.Conclusions Molecular subtype is not independent risk factor for breast cancer patients' 5-year overall survival and disease free survival.